MX2009008877A - Variantes de transglutaminasa con especificidad mejorada. - Google Patents
Variantes de transglutaminasa con especificidad mejorada.Info
- Publication number
- MX2009008877A MX2009008877A MX2009008877A MX2009008877A MX2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A MX 2009008877 A MX2009008877 A MX 2009008877A
- Authority
- MX
- Mexico
- Prior art keywords
- improved specificity
- variants
- transglutaminase
- transglutaminase variants
- improved
- Prior art date
Links
- 108060008539 Transglutaminase Proteins 0.000 title abstract 2
- 102000003601 transglutaminase Human genes 0.000 title abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- 241001495137 Streptomyces mobaraensis Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
Abstract
Se proporcionan variantes de transglutaminasa de Streptoverticillium ladakanum, variantes las cuales tienen una selectividad mejorada para Gln-141 de la hormona de crecimiento humana.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07102886 | 2007-02-22 | ||
PCT/EP2007/058571 WO2008020075A1 (en) | 2006-08-18 | 2007-08-17 | Transglutaminase variants with improved specificity |
PCT/EP2008/052190 WO2008102007A1 (en) | 2007-02-22 | 2008-02-22 | Transglutaminase variants with improved specificity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008877A true MX2009008877A (es) | 2009-08-28 |
Family
ID=39709668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008877A MX2009008877A (es) | 2007-02-22 | 2008-02-22 | Variantes de transglutaminasa con especificidad mejorada. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100099610A1 (es) |
EP (2) | EP2118132A1 (es) |
JP (2) | JP2010518842A (es) |
KR (1) | KR20090123857A (es) |
CN (1) | CN101679503A (es) |
AU (1) | AU2008219238A1 (es) |
BR (1) | BRPI0808014A2 (es) |
CA (1) | CA2678669A1 (es) |
MX (1) | MX2009008877A (es) |
RU (1) | RU2009134725A (es) |
WO (2) | WO2008102007A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012356894B2 (en) | 2011-12-23 | 2018-01-18 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP3010548A1 (en) | 2013-06-21 | 2016-04-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
CN113332449B (zh) | 2014-06-12 | 2023-12-22 | 石药集团巨石生物制药有限公司 | 酶法制备同质的抗体-药物缀合物 |
CN107177582B (zh) * | 2016-02-16 | 2018-05-22 | 上海青瑞食品科技有限公司 | 一种液体酶制剂及制备方法 |
EP3500574B1 (en) | 2016-08-19 | 2021-11-24 | Bristol-Myers Squibb Company | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
CA3177215A1 (en) | 2017-09-19 | 2019-03-28 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
CA3080512A1 (en) * | 2017-11-07 | 2019-05-16 | Codexis, Inc. | Transglutaminase variants |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
IL312163A (en) | 2018-05-29 | 2024-06-01 | Bristol Myers Squibb Co | Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
WO2020188061A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
CN111944778B (zh) * | 2020-08-14 | 2022-06-21 | 安徽医学高等专科学校 | 谷氨酰胺转胺酶突变体及其编码基因和应用 |
KR20230069211A (ko) | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
KR20230096052A (ko) | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
CN118159298A (zh) | 2021-10-25 | 2024-06-07 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的方法 |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010871A (en) * | 1994-09-29 | 2000-01-04 | Ajinomoto Co., Inc. | Modification of peptide and protein |
JPH1175876A (ja) * | 1997-07-04 | 1999-03-23 | Ajinomoto Co Inc | 新規な微生物トランスグルタミナーゼの製造法 |
CA2391961C (en) * | 1999-09-30 | 2008-12-02 | Yoshimi Kikuchi | Process for producing transglutaminase |
BR0113304A (pt) * | 2000-08-17 | 2004-01-06 | Ajinomoto Kk | Método para planejar e preparar uma transglutaminase mutante, mtg mutante transglutaminase mutante, gene, dna recombinante, microorganismos, método para produzir uma mtg mutante ou uma transglutaminase mutante, e, cristais de mtg monoclìnicos |
US6660510B2 (en) * | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
AU2003213718A1 (en) * | 2002-03-01 | 2003-09-16 | Szu-Yi Chou | Method of producing antigens |
US7101695B2 (en) * | 2002-03-01 | 2006-09-05 | Szu-Yi Chou | Method of producing transglutaminase having broad substrate activity |
CN1243022C (zh) * | 2003-10-17 | 2006-02-22 | 华东师范大学 | 生物修饰重组人生长激素复合物及其制备方法 |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
CN103215328B (zh) * | 2004-01-21 | 2016-08-03 | 诺和诺德医疗保健公司 | 转谷氨酰胺酶介导的肽的接合 |
TW200716179A (en) * | 2005-06-15 | 2007-05-01 | Novo Nordisk As | Transglutaminase mediated conjugation of growth hormone |
CN101287757A (zh) * | 2005-08-18 | 2008-10-15 | 诺沃-诺迪斯克保健股份有限公司 | 特异性改进的转谷氨酰胺酶变异体 |
-
2008
- 2008-02-22 JP JP2009550721A patent/JP2010518842A/ja active Pending
- 2008-02-22 EP EP08709183A patent/EP2118132A1/en not_active Withdrawn
- 2008-02-22 US US12/527,247 patent/US20100099610A1/en not_active Abandoned
- 2008-02-22 AU AU2008219238A patent/AU2008219238A1/en not_active Withdrawn
- 2008-02-22 BR BRPI0808014-3A2A patent/BRPI0808014A2/pt not_active IP Right Cessation
- 2008-02-22 MX MX2009008877A patent/MX2009008877A/es unknown
- 2008-02-22 WO PCT/EP2008/052190 patent/WO2008102007A1/en active Application Filing
- 2008-02-22 WO PCT/EP2008/052194 patent/WO2008102008A1/en active Application Filing
- 2008-02-22 US US12/527,451 patent/US20100087371A1/en not_active Abandoned
- 2008-02-22 EP EP08717052A patent/EP2121744A1/en not_active Withdrawn
- 2008-02-22 KR KR1020097016491A patent/KR20090123857A/ko not_active Application Discontinuation
- 2008-02-22 CN CN200880005249A patent/CN101679503A/zh not_active Withdrawn
- 2008-02-22 JP JP2009550722A patent/JP2010518843A/ja active Pending
- 2008-02-22 RU RU2009134725/10A patent/RU2009134725A/ru unknown
- 2008-02-22 CA CA002678669A patent/CA2678669A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2010518843A (ja) | 2010-06-03 |
CA2678669A1 (en) | 2008-08-28 |
JP2010518842A (ja) | 2010-06-03 |
EP2118132A1 (en) | 2009-11-18 |
US20100099610A1 (en) | 2010-04-22 |
CN101679503A (zh) | 2010-03-24 |
EP2121744A1 (en) | 2009-11-25 |
WO2008102008A1 (en) | 2008-08-28 |
US20100087371A1 (en) | 2010-04-08 |
RU2009134725A (ru) | 2011-03-27 |
KR20090123857A (ko) | 2009-12-02 |
BRPI0808014A2 (pt) | 2014-06-17 |
WO2008102007A1 (en) | 2008-08-28 |
AU2008219238A1 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008877A (es) | Variantes de transglutaminasa con especificidad mejorada. | |
AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
PH12015501953A1 (en) | Substituted nucleotide analogs | |
WO2009108860A8 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
MX2009013593A (es) | Formulaciones de anticuerpos. | |
MX2010001073A (es) | Metodo para producir una bebida lactea acidificada. | |
MX2011006334A (es) | Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol. | |
WO2010065815A3 (en) | Mini-hepcidin peptides and methods of using thereof | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
WO2008091908A3 (en) | Human cancer stem cells | |
BRPI0714648B8 (pt) | preparação de 3-[(1r,2r)-3-(dimetilamino)-1etil-2-metilpropil] fenol | |
TW200626171A (en) | Fixed dosing of HER antibodies | |
WO2011005595A3 (en) | 2-5a analogs and their methods of use | |
WO2010003520A3 (en) | Anti-tumor immunotherapy | |
SI2404995T1 (sl) | Encim, povezan s sintezo ekvola | |
HK1139705A1 (en) | Growth medium for c. histolyticum without ingredients of mamalian sources | |
MX2009008660A (es) | Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos. | |
MX2012004404A (es) | Caldo de fermentacion de actinomicetos con actividad insecticida. | |
HK1184823A1 (en) | Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and method for producing aglycones using the microorganism, the oxidoreductase and the gene | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
WO2009153047A3 (de) | Biotechnologische herstellung von acrylsäure | |
WO2013024267A3 (en) | Stabilized compositions against ionising radiation | |
EP2099458A4 (en) | COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS | |
WO2008058111A3 (en) | Methods of preparing halohydroxypropyltrialkylammonium halides | |
IN2012DN01846A (es) |